News
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...
Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...
Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $32.00. The company’s shares closed yesterday at $27.64. Take advantage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results